Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(03): 243-248
DOI: 10.1055/s-0042-1742596
Original Article
Lung Cancer

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review

Satvik Khaddar
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Akhil Kapoor 
2   Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
,
Vanita Noronha 
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Vijay M. Patil
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nandini Menon 
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Abhishek Mahajan
3   Department of Radiodiagnosis and Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Amit Janu
3   Department of Radiodiagnosis and Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rajiv Kumar
4   Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nilendu Purandare
5   Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Kumar Prabhash
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Zoom Image
Akhil Kapoor

Introduction The prognosis of anaplastic lymphoma kinase (ALK) fusion-positive metastatic non-small cell lung cancer (mNSCLC) patients has improved drastically since the introduction of targeted therapies. Apart from age, performance status, and type of driver mutation in a mNSCLC, prognosis also depends on baseline metastatic sites number as well as location with liver metastases being a poor prognostic factor. However, the clinical and prognostic association of baseline liver metastases in ALK fusion-positive mNSCLC is not well known.

Material and Methods We performed a retrospective analysis of ALK fusion-positive mNSCLC patients to assess prognostic impact of liver metastases. Records were obtained from lung cancer audit database and electronic medical records. Patients were started on either chemotherapy, ALK-directed tyrosine kinase inhibitors, or given best supportive care as per the clinical scenario. Radiological response was assessed every 2 to 3 months or earlier at clinical suspicion of progressive disease. Adverse events were evaluated as per Common Terminology Criteria for Adverse Events v4.02.

Results A total of 441 patients were screened, out of which 76 had baseline liver metastases. Median age was 49 years with 64.5% males. Median progression-free survival (mPFS) was 14.2 months (95% confidence interval [CI] 8.9–19.4) in patients with baseline liver metastases. In patients who received first-line ALK inhibitor therapy versus who received first-line chemotherapy, mPFS was significantly better in the ALK-directed therapy subgroup, 15.3 months (95% CI 11.7–18.9) versus 5.9 months (95% CI 2.7–9.1), respectively (hazard ratio [HR] 0.3 [95% CI 0.17–0.54]; p < 0.001). Median overall survival (mOS) was 27.6 months (95% CI 17.4–37.7) in patients with baseline liver metastases which was not statistically significant from patients without baseline liver metastases which was 32.3 months (95% CI 28.8–35.7) (HR 1.32 [95% CI 0.91–1.9]; p = 0.22). Use of ALK-directed therapy in patients with baseline liver metastases resulted in better OS, mOS not reached versus 15.7 months (95% CI 2.7–28.8) in the chemotherapy group (HR 0.33 [95% CI 0.16—0.67]; p < 0.001).

Conclusion In patients with ALK fusion-positive mNSCLC, baseline liver metastases was not found to be an independent prognostic factor. However, the use of ALK-directed therapy resulted in a significantly better PFS and OS as compared with chemotherapy in patients with baseline liver metastases. This underscores the importance of the use of ALK-directed therapy whenever feasible in this group of patients.

Keywords

ALK - chemotherapy - crizotinib - liver metastases - NSCLC


Publication History

Article published online:
22 March 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Soda M, Choi YL, Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566
    CrossrefPubMedGoogle Scholar
  • 2 Chandrani P, Prabhash K, Prasad R. et al. Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann Oncol 2017; 28 (03) 597-603
    CrossrefPubMedGoogle Scholar
  • 3 Mok T, Camidge DR, Gadgeel SM. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020; 31 (08) 1056-1064
    CrossrefPubMedGoogle Scholar
  • 4 Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol 2003; 20 (01) 25-28
    CrossrefPubMedGoogle Scholar
  • 5 Li J, Zhu H, Sun L, Xu W, Wang X. Prognostic value of site-specific metastases in lung cancer: a population based study. J Cancer 2019; 10 (14) 3079-3086
    CrossrefPubMedGoogle Scholar
  • 6 Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012; 118 (18) 4502-4511
    CrossrefPubMedGoogle Scholar
  • 7 Chang YP, Chen YM, Lai CH. et al. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS One 2017; 12 (06) e0178676
    CrossrefPubMedGoogle Scholar
  • 8 Pacheco JM, Gao D, Smith D. et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol 2019; 14 (04) 691-700
    CrossrefPubMedGoogle Scholar
  • 9 Noronha V, Ramaswamy A, Patil VM, Joshi A, Chougule A, Kane S. et al. ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country [published correction appears in PLoS One. 2016 Dec 9;11(12): e0168221]. PLoS One 2016; 11 (09) e0160752
    CrossrefPubMedGoogle Scholar
  • 10 Wu SG, Kuo YW, Chang YL. et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012; 7 (01) 98-104
    CrossrefPubMedGoogle Scholar
  • 11 Chang L, Hui Y, Long Q. et al. Real world experience of crizotinib in 104 patients with ALK rearrangement non-small-cell lung cancer in a single Chinese cancer center. Front Oncol 2019; 9: 1116
    CrossrefPubMedGoogle Scholar
  • 12 Del Valle MFF, Chang AY. Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. J Thorac Dis 2019; 11 (09) 3864-3873
    CrossrefPubMedGoogle Scholar
  • 13 Solomon BJ, Mok T, Kim D-W. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177
    CrossrefPubMedGoogle Scholar